MedPath

Pilot study of FOLFOX or XELOX Therapy Versus FOLFOX or XELOX + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colon Cancer

Phase 4
Conditions
Colon cancer
Registration Number
JPRN-UMIN000006134
Lead Sponsor
Tokai University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patient with metachronous or synchronous cancer 2.Patient who requires continuous use of phenytoin or warfarin potassium 3.Patient who has experienced serious drug allergy over grade 3 in the past 4.Patient with serious complications including paralysis of intestine, ileus, interstitial pneumonitis, fibroid lung, uncontrollable diabetes mellitus, heart insufficiency, renal insufficiency or hepatic insufficiency 5.Patient who is pregnant or in lactation, or wish to become pregnant during this study 6.Male patient who intends to make someone pregnant during this study 7.Patient with HIV positive 8.Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath